Tandem Diabetes Care 

€36.75
60
+€0+0% Wednesday 06:00

統計

當日最高
-
當日最低
-
52週最高
-
52週最低
-
成交量
-
平均成交量
-
市值
2.85B
市盈率
-
股息收益率
-
股息
-

即將到來

收益

30Oct預期
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
下一個
-1.73
-1.24
-0.74
-0.25
預期每股收益
-0.3708021246
實際每股收益
N/A

人們還關注

此列表基於在 Stock Events 上關注 TD5A.F 的人的關注列表。這不是投資建議。

競爭者

這個列表是基於最近市場事件的分析。這不是投資建議。

分析師評級

54.67平均價格目標
最高估價為 €75。
來自過去 6 個月內的 12 個評級。這不是投資建議。
買入
83%
持有
17%
賣出
0%

關於

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Show more...
首席執行官
Mr. John F. Sheridan
員工
2400
國家
US
ISIN
US8753722037
WKN
000A2H5BX

上市公司